Sort   by:  
 Page size 
ProteomicsFingolimod and remyelination - Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model
Remyelinating substances could be an essential supplement to immunomodulatory medications, optimizing the treatment of multiple sclerosis (MS) patients. Fingolimod is a sphingosine-1-phosphate receptor (S1PR) modulator and crosses the blood-brain barrier. Central nervous system (CNS) cells express S...
ORGANISM(S): Mus musculus (Mouse) 
2019-11-20 | PXD012676 | Pride
Brain Cpz Tissue Proteomics Tmt Mass spectrometry Qe-hf Fingolimod Mouse Multiplexing 
TranscriptomicsTranscriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, gene level]
We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populat...
ORGANISM(S): Homo sapiens 
2015-09-19 | E-GEOD-73081 | biostudies-arrayexpress
TranscriptomicsTranscriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD8+ cells, exon level]
We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populat...
ORGANISM(S): Homo sapiens 
2015-09-19 | E-GEOD-73172 | biostudies-arrayexpress
TranscriptomicsTranscriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, gene level]
We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populat...
ORGANISM(S): Homo sapiens 
2015-09-19 | E-GEOD-73079 | biostudies-arrayexpress
TranscriptomicsTranscriptome data of multiple sclerosis patients receiving fingolimod therapy [HTA-2_0, CD4+ cells, exon level]
We analyzed the gene expression patterns of different blood cell types before and during fingolimod treatment in a group of patients with relapsing-remitting multiple sclerosis (RRMS). Affymetrix Human Transcriptome Arrays (HTA) 2.0 were used to obtain gene expression profiles of immune cell populat...
ORGANISM(S): Homo sapiens 
2015-09-19 | E-GEOD-73080 | biostudies-arrayexpress
ProteomicsFingolimod effects on the brain are mediated through biochemical modulation of bioenergetics, autophagy and neuroinflammatory networks
Fingolimod (FTY720) is an oral drug approved by the Food and Drug Administration (FDA) for management of Multiple Sclerosis (MS) symptoms, which has also shownbeneficial effects against Alzheimer’s (AD) and Parkinson’s (PD) diseases pathologies. Although an extensive effort has been made to identif...
ORGANISM(S): Mus musculus (Mouse) 
2022-08-09 | PXD034427 | Pride
Fingolimod Brain Frontal cortex Cerebellum Proteomics 
GenomicsTranscriptomic profile of multiple sclerosis patients treated with fingolimod
Transcriptomic profile of multiple sclerosis patients treated with fingolimod
PRJNA1054089 | ENA
GenomicsSerum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment
Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment
PRJNA588268 | ENA
TranscriptomicsTranscriptomic profile of multiple sclerosis patients treated with fingolimod
Fingolimod is an immunomodulatory sphingosine-1-phosphate (S1P) analogue approved for the treatment of relapsing-remitting multiple sclerosis (RRMS). The identification of biomarkers of clinical response to fingolimod is a major necessity in MS to identify optimal responders and avoid the risk of di...
ORGANISM(S): Homo sapiens 
2024-01-31 | GSE250453 | GEO
GenomicsTranscriptome data of multiple sclerosis patients receiving fingolimod therapy
Transcriptome data of multiple sclerosis patients receiving fingolimod therapy
PRJNA296075 | ENA
Sort   by:  
 Page size